Project Details
Description
Intraperitoneal FT538 with Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/22 → 12/31/23 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.